Benitec Hoping to Start OPMD Gene Therapy Trial in US, EU Next Year

Benitec Hoping to Start OPMD Gene Therapy Trial in US, EU Next Year

305362

Benitec Hoping to Start OPMD Gene Therapy Trial in US, EU Next Year

Benitec Biopharma is taking steps to get the needed regulatory clearances to start clinical testing in Europe and the U.S. of BB-301, its experimental gene therapy for oculopharyngeal muscular dystrophy or OPMD, a type of the genetic disease that typically first affects the eyelids and the throat. The company said it is planning to launch a Phase 1b/2a clinical trial of BB-301 next year. The announcement follows a successful scientific advice meeting with the National…

You must be logged in to read/download the full post.